secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYNAVAX TECHNOLOGIES CORP (—)
CIK:        0001029142
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001193125-25-332264
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanofi to acquire Dynavax for $15.50/share in cash, total equity value ~$2.2B
-----------------------------------------------------------------------------

- Sanofi to acquire Dynavax for $15.50/share cash, total equity value ~$2.2B.
- Offer price represents ~39% premium to Dec 23, 2025 close and ~46% over 3-month VWAP.
- Acquisition includes marketed hepatitis B vaccine HEPLISAV-B and Phase 1/2 shingles candidate Z-1018.
- Transaction expected to close Q1 2026, subject to majority tender, HSR clearance, other conditions.
- Dynavax board unanimously approved; officers Novack and Janssen to continue roles until close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029142/000119312525332264/0001193125-25-332264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029142/000119312525332264/d82616d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-332264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer